Live Breaking News & Updates on Gastroesophageal Junction

Stay updated with breaking news from Gastroesophageal junction. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

U.S. FDA ACKNOWLEDGES ASTELLAS' RESUBMISSION OF BIOLOGICS LICENSE APPLICATION FOR ZOLBETUXIMAB AND SETS NEW ACTION DATE

/PRNewswire/ Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA). ....

Japan , United-states , Australia , Canada , Tokyo , Shitara , Aichi , United-kingdom , American , America , Moitreyee-chatterjee-kishore , Naoki-okamura

ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update

ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Colorado , United-states , California , Chicago , Illinois , San-diego , Texas , American , Jason-lettmann , Allison-dillon , Academic-gi-cancer-consortium , Development-rd-expenses

Keytruda Combo Boosts Survival in Gastric Cancer Subtype

For certain patients with HER2-positive gastric cancers, a Keytruda treatment combination has shown promising survival outcomes. ....

Merck-research-laboratories , National-cancer-institute , Survival-outcomes , Gastroesophageal-junction , Marjorie-green , Merck-research , News , Gastric-cancer , Gastroesophageal-junction-cancer , Keytruda ,

FDA Grants Fast Track Designation to PT886 for the Treatment of Pancreatic Cancer

PT886 (Phanes Therapeutics) received fast track designation 2 years after receiving orphan drug designation by the FDA. ....

United-states , Ming-wang , Phanes-therapeutics-inc , Phanes-therapeutics , Patients-with , Advanced-gastric , Gastroesophageal-junction , Fast-track , Therapeutics-announces-first-patient-dosed , Announces-clinical-trial-collaboration , Supply-agreement ,

BeiGene, Ltd.: BeiGene's Biologics License Application for TEVIMBRA (tislelizumab) for First-Line Gastric or Gastroesophageal Junction Cancers Accepted by FDA

BeiGene, Ltd.: BeiGene's Biologics License Application for TEVIMBRA (tislelizumab) for First-Line Gastric or Gastroesophageal Junction Cancers Accepted by FDA
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Beijing , China , United-states , France , Laversanne , Rhôalpes , Cambridge , Cambridgeshire , United-kingdom , Lesen , Aquitaine , American